Anti-heparin platelet factor 4 antibodies in systemic lupus erythaematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome

Annals of the Rheumatic Diseases

Volumn 67, Issue 3, 2008, Pages 395-401

  Alpert, D ^a,c   Mandl, L A ^d   Erkan, D ^a   Yin, W ^b   Peerschke, E I ^b   Salmon, J E ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c JERSEY SHORE UNIVERSITY MEDICAL CENTER   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN PLATELET FACTOR 4 ANTIBODY; IMMUNOGLOBULIN M; PHOSPHOLIPID ANTIBODY;

ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; COMORBIDITY; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOADSORPTION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SEROTONIN RELEASE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; HEPARIN; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PLATELET FACTOR 4; RETROSPECTIVE STUDIES;

EID: 39549086338     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.074476     Document Type: Article

References (37)

1. Franchini M. Heparin-induced thrombocytopenia: an update. Thromb J 2005;3:14.
2. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994;93:81-8.
3. Warkentin TE, Sheppard JA, Moore JC, Moore KM, Sigouin CS, Kelton JG. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med 2005;146:341-6.
4. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000;96:1703-8.
5. Matsuo T, Suzuki S, Matsuo M, Kobayasi H. Preexisting antibodies to platelet factor 4-heparin complexes in patients with acute coronary syndrome who have no history of heparin exposure. Pathophysiol Haemost Thromb 2005;34:18-22.
6. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42:1309-11.
7. Atsumi T, Furukawa S, Amengual O, Koike T. Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis. Lupus 2005;14:499-504.
8. Sammaritano LR. Antiphospholipid syndrome: review. South Med J 2005;98:617-25.
9. Gruel Y. Antiphospholipid syndrome and heparin-induced thrombocytopenia: update on similarities and differences. J Autoimmun 2000;15:265-8.
10. Bourhim M, Darnige L, Legallais C, Arvieux J, Cevallos R, Pouplard C, et al. Anti-β2-glycoprotein 1 antibodies recognizing platelet factor 4-heparin complex in antiphospholipid syndrome in patient substantiated with mouse model. J Mol Recognit 2003;16:125-30.
11. de Larranaga G, Martinuzzo M, Bocassi A, Fressart MM, Forastiero R. Heparin-platelet factor 4 induced antibodies in patients with either autoimmune or alloimmune antiphospholipid antibodies. Thromb Haemost 2002;88:371-3.
12. Lasne D, Saffroy R, Bachelot C, Vincenot A, Rendu F, Papo T, et al. Tests for heparin-induced thrombocytopenia in primary antiphospholipid syndrome. Br J Haematol 1997;97:939.
13. Martin-Toutain I, Piette J, Diemert M, Faucher C, Jobic L, Ankri A. High prevalence of antibodies to platelet factor 4 heparin in patients with antiphospholipid antibodies in absence of heparin-induced thrombocytopenia. Lupus 2007;16:79-83.
14. Martinuzzo ME, Forastiero RR, Adamczuk Y, Pombo G, Carreras LO. Antiplatelet factor 4-heparin antibodies in patients with antiphospholipid antibodies. Thromb Res 1999;95:271-9.
15. Akhter E, Ortel T, Klemp KF, Petri M. Association between anti-heparin antibodies, antiphospholipid antibodies and thrombotic events [abstract]. Arthritis Rheum 2006;54(Suppl):S554.
16. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
17. Merkel PA, Chang Y, Pierangeli SS, Harris EN, Polisson RP. Comparison between the standard anticardiolipin antibody test and a new phospholipid test in patients with connective tissue diseases. J Rheumatol 1999;26:591-6.
18. Pierangeli S, Henderson V, Pappalardo E, Pierangeli H, Rice J, Padilla P, et al. Evaluation of several ELISA tests used in the diagnosis of antiphospholipid syndrome in a large cohort of patient samples [abstract]. Arthritis Rheum 2006;54(Suppl):S553.
19. Harris EN, Pierangeli S, Birch D. Anticardiolipin wet workshop report. Fifth international symposium on antiphospholipid antibodies. Am J Clin Pathol 1994;101:616-24.
20. Peerschke EI, Zucker MB. Fibrinogen receptor exposure and aggregation of human blood platelets produced by ADP and chilling. Blood 1981;57:663-70.
21. Peerschke EI. Induction of human platelet fibrinogen receptors by epinephrine in the absence of released ADP. Blood 1982;60:71-7.
22. Kelton JG, Sheridan D, Santos A, Smith J, Steeves K, Smith C, et al. Heparin-induced thrombocytopenia: laboratory studies. Blood 1988;72:925-30.
23. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986;67:27-30.
24. Bennett-Guerrero E, Slaughter TF, White WD, Welsby IJ, Greenberg CS, El-Moalem H, et al. Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery. J Thorac Cardiovasc Surg 2005;130:1567-72.
25. Walenga JM, Jeske WP, Prechel MM, Bakhos M. Newer insights on the mechanism of heparin-induced thrombocytopenia. Semin Thromb Hemost 2004;30(Suppl 1):57-67.
26. Amiral J, Wolf M, Fischer A, Boyer-Neumann C, Vissac A, Meyer D. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 1996;92:954- 9.
27. Juhl D, Eichler P, Lubenow N, Strobel U, Wessel A, Greinacher A. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol 2006;76:420-6.
28. Untch B, Ahmad S, Jeske WP, Messmore HL, Hoppensteadt DA, Walenga JM, et al. Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. The pathogenic role of IgG. Thromb Res 2002;105:117-23.
29. Holers VM, Girardi G, Mo L, Guthridge JM, Molina H, Pierangeli SS, et al. Complement C3 activation is reguired for antiphospholipid antibody-induced fetal loss. J Exp Med 2002;195:211-20.
30. Pierangeli SS, Girardi G, Vega-Ostertag M, Liu X, Espinola RG, Salmon J. Reguirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005;52:2120-4.
31. Salmon JE, Girardi G, Holers VM. Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis 2002;61(Suppl 2):ii46-50.
32. Davis WD, Brey RL. Antiphospholipid antibodies and complement activation in patients with cerebral ischemia. Clin Exp Rheumatol 1992;10:455-60.
33. Munakata Y, Saito T, Matsuda K, Seino J, Shibata S, Sasaki T. Detection of complement-fixing antiphospholipid antibodies in association with thrombosis. Thromb Haemost 2000;83:728-31.
34. Shamonki JM, Salmon JE, Hyjek E, Baergen RN. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 2007;196:167e1-5.
35. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001;344:1286-92.
36. Blank M, Shoenfeld Y, Tavor S, Praprotnik S, Boffa MC, Weksler B, et al. Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int Immunol 2002;14:121-9.
37. Warkentin TE, Jay RM, Makris M, Kelton JG. Platelet-activating anti-platelet factor 4/polyanion antibodies without preceding heparin therapy: a transient autoimmune disorder resembling heparin-induced thrombocytopenia ("spontaneous hit") [abstract]. Blood 2006;108:108.